Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 3 de 3
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Life Sci Alliance ; 7(2)2024 02.
Article de Anglais | MEDLINE | ID: mdl-37957015

RÉSUMÉ

Deregulation of the Hippo pathway is a driver for cancer progression and treatment resistance. In the context of gastric cancer, YAP1 is a biomarker for poor patient prognosis. Although genomic tumor profiling provides information of Hippo pathway activation, the present study demonstrates that inhibition of Yap1 activity has anti-tumor effects in gastric tumors driven by oncogenic mutations and inflammatory cytokines. We show that Yap1 is a key regulator of cell metabolism, proliferation, and immune responses in normal and neoplastic gastric epithelium. We propose that the Hippo pathway is targetable across gastric cancer subtypes and its therapeutic benefits are likely to be mediated by both cancer cell-intrinsic and -extrinsic mechanisms.


Sujet(s)
Tumeurs de l'estomac , Humains , Tumeurs de l'estomac/génétique , Tumeurs de l'estomac/métabolisme , Tumeurs de l'estomac/anatomopathologie , Microenvironnement tumoral , Protéines adaptatrices de la transduction du signal/génétique , Protéines adaptatrices de la transduction du signal/métabolisme , Facteurs de transcription/génétique , Facteurs de transcription/métabolisme , Voie de signalisation Hippo , Facteur de transcription STAT-3/métabolisme
2.
PLoS One ; 10(9): e0136817, 2015.
Article de Anglais | MEDLINE | ID: mdl-26334628

RÉSUMÉ

The development of antigen-targeted therapeutics is dependent on the preferential expression of tumor-associated antigens (TAA) at targetable levels on the tumor. Tumor-associated antigens can be generated de novo or can arise from altered expression of normal basal proteins, such as the up-regulation of human epidermal growth factor receptor 2 (Her2/ErbB2). To properly assess the development of Her2 therapeutics in an immune tolerant model, we previously generated a transgenic mouse model in which expression of the human Her2 protein was present in both the brain and mammary tissue. This mouse model has facilitated the development of Her2 targeted therapies in a clinically relevant and suitable model. While heterozygous Her2+/- mice appear to develop in a similar manner to wild type mice (Her2-/-), it has proven difficult to generate homozygous Her2+/+ mice, potentially due to embryonic lethality. In this study, we performed whole genome sequencing to determine if the integration site of the Her2 transgene was responsible for this lethality. Indeed, we report that the Her2 transgene had integrated into the Pds5b (precocious dissociation of sisters) gene on chromosome 5, as a 162 copy concatemer. Furthermore, our findings demonstrate that Her2+/+ mice, similar to Pds5b-/- mice, are embryonic lethal and confirm the necessity for Pds5b in embryonic development. This study confirms the value of whole genome sequencing in determining the integration site of transgenes to gain insight into associated phenotypes.


Sujet(s)
Protéines de liaison à l'ADN/génétique , Gènes létaux , Gènes erbB-2 , Homozygote , Facteurs de transcription/génétique , Animaux , Lignée cellulaire tumorale , Cartographie chromosomique , Exons , Mort foetale , Humains , Souris , Souris transgéniques , Phénotype
3.
Proc Natl Acad Sci U S A ; 102(21): 7659-64, 2005 May 24.
Article de Anglais | MEDLINE | ID: mdl-15897450

RÉSUMÉ

The zinc finger protein LMO4 is overexpressed in a high proportion of breast carcinomas. Here, we report that overexpression of a mouse mammary tumor virus (MMTV)-Lmo4 transgene in the mouse mammary gland elicits hyperplasia and mammary intraepithelial neoplasia or adenosquamous carcinoma in two transgenic strains with a tumor latency of 13-18 months. To investigate cellular processes controlled by LMO4 and those that may be deregulated during oncogenesis, we used RNA interference. Down-regulation of LMO4 expression reduced proliferation of human breast cancer cells and increased differentiation of mouse mammary epithelial cells. Furthermore, small-interfering-RNA-transfected breast cancer cells (MDA-MB-231) had a reduced capacity to migrate and invade an extracellular matrix. Conversely, overexpression of LMO4 in noninvasive, immortalized human MCF10A cells promoted cell motility and invasion. Significantly, in a cohort of 159 primary breast cancers, high nuclear levels of LMO4 were an independent predictor of death from breast cancer. Together, these findings suggest that deregulation of LMO4 in breast epithelium contributes directly to breast neoplasia by altering the rate of cellular proliferation and promoting cell invasion.


Sujet(s)
Tumeurs du sein/génétique , Expression des gènes , Protéines à homéodomaine/métabolisme , Glandes mammaires animales/anatomopathologie , Invasion tumorale/génétique , Facteurs de transcription/métabolisme , Protéines adaptatrices de la transduction du signal , Animaux , Technique de Western , Tumeurs du sein/métabolisme , Lignée cellulaire tumorale , Mouvement cellulaire/génétique , Prolifération cellulaire , Amorces ADN , Femelle , Technique d'immunofluorescence , Protéines à homéodomaine/génétique , Humains , Hyperplasie/métabolisme , Immunohistochimie , Protéines à domaine LIM , Glandes mammaires animales/métabolisme , Virus de la tumeur mammaire de la souris , Souris , Souris de lignée BALB C , Souris transgéniques , Nouvelle-Galles du Sud , Interférence par ARN , Facteurs de risque , Facteurs de transcription/génétique , Transfection , Transgènes/génétique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...